City
Epaper

Gene-based blood test may help predict early signs of cancer's return

By IANS | Updated: April 16, 2025 15:27 IST

New Delhi, April 16 Monitoring blood levels of DNA fragments shed by dying tumour cells may accurately predict ...

Open in App

New Delhi, April 16 Monitoring blood levels of DNA fragments shed by dying tumour cells may accurately predict cancer recurrence, according to a new study.

Researchers at New York University-Langone Health, US, focussed on nearly 600 men and women from Europe, North America, and Australia, with stage III melanoma -- among the most aggressive forms of skin cancer.

The study showed that approximately 80 per cent of skin cancer patients with detectable levels of circulating tumour DNA (ctDNA), before they started treatment to suppress their tumours, went on to experience recurrence.

The disease was also found to return more than four times faster in this group than in those with no detectable levels of the biomarker, and the higher their levels, the faster the cancer returned.

"Our findings suggest that circulating tumour DNA tests could help oncologists identify which melanoma patients are most likely to respond well to therapy," said study lead author Mahrukh Syeda, a research scientist at NYU Grossman School of Medicine.

"In the future, such assessments may be used routinely in the clinic to help guide treatment decisions," added Syeda.

In the study, published in the journal The Lancet Oncology, the team also found that nearly all of those with detectable levels of ctDNA at three, six, nine, or 12 months into treatment experienced melanoma recurrence.

As a result, the researchers said, if the gene fragments are not observable prior to therapy but appear later on, this could indicate that the disease might be worsening.

Syeda said that the ctDNA method works by focusing on the most common mutations in the genetic code in melanoma cells.

The mutated DNA spills into surrounding blood as the cells break down.

Further, the team showed that assessing ctDNA levels were as good or better at predicting recurrence than other experimental tests that examine a tumour itself, such as those that measure immune activity within a group of cancer cells.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Open in App

Related Stories

BusinessMoody’s keeps India rating at Baa3 with stable outlook

NationalGujarat CM, Dy CM press Kharge with questions after ‘illiterate’ remark, seek apology

Health'Murderous Corruption': Rahul Gandhi hits out at AINRC-BJP govt over 'fake drugs' in Puducherry

National'Murderous Corruption': Rahul Gandhi hits out at AINRC-BJP govt over 'fake drugs' in Puducherry

NationalBadrinath Dham preparations reviewed ahead of April 23 opening; Temple Committee CEO sets April 20 deadline for works

Technology Realted Stories

TechnologyIndia’s white-collar job market ends this fiscal strong led by non‑IT, AI hiring

TechnologyIndian Railways approves Rs 1,364 crore to expand Kavach, modern signalling systems

TechnologyOver 18 crore LPG cylinders delivered since March 1, adequate rice and wheat stocks available: Govt

Technology16 Indian-flagged vessels with 433 seafarers remain in Persian Gulf: Govt

TechnologyMusk' Tesla opens 1st in-mall charging station in Navi Mumbai